에피네프린 자동 주사기 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the epinephrine autoinjector market size was valued at USD 3.45 billion in 2025 and estimated to grow from USD 3.72 billion in 2026 to reach USD 5.43 billion by 2031, at a CAGR of 7.84% during the forecast period (2026-2031).

This report is Segmented by Dosage Strength (0. 10 Mg, 0. 15 Mg, 0. 30 Mg, and 0. 50 Mg), Age-Group ( 12 Years), End-User (Hospitals, Clinics, Homecare Individuals, Schools & Universities, and Emergency Medical Services), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Epinephrine Autoinjector Market Trends and Insights

Escalating Global Burden of Severe Allergic Disorders

Rapid growth in food, drug and environmental allergies is reshaping demand patterns. Approximately 40 million Americans report Type I allergic reactions each year. Pediatric incidence is climbing fastest, with 1 in 13 children now living with food allergies. As clinicians adopt earlier screening and community health campaigns stress rapid response, prescription volumes for rescue devices have multiplied. The dynamic is self-reinforcing: wider diagnosis raises market penetration, more devices in circulation improve outcomes and positive outcomes encourage additional screening. Manufacturers are responding with age-specific doses and needle-free formats, ensuring that new patient cohorts find a comfortable delivery option.

Favorable Regulatory and Reimbursement Ecosystem

Flexible regulators and payors are clearing a path for broader access. The FDA approved neffy nasal spray in 2024 and quickly added a pediatric indication in March 2025. National formularies at OptumRx, Cigna Healthcare and Navitus now include the product, together reaching about 20 million covered lives. New York State has capped the consumer price of a two-pack at USD 100 starting in 2026, removing a key barrier in a price-sensitive demographic. Europe mirrored the trend by granting central approval plus eight-year data exclusivity for EURneffy, sending a clear signal that innovation addressing unmet need will receive regulatory support. Meanwhile, Medicare Part D classifies many generics as preferred, pushing down patient co-pays and lifting fill rates in senior populations.

Persistently High Out-of-Pocket Costs

Although generic expansion is narrowing list prices, many United States insurance plans carry high deductibles, leaving families with average prescription expenses of USD 328.03 and mean out-of-pocket costs of USD 31.90. Households typically purchase multiple packs to cover home, school and travel, compounding cost burden. Plan formularies also shift annually, forcing patients to navigate new authorisation rules. Assistance programmes cap co-pays for some, yet the uninsured remain exposed. Financial strain can delay refills past expiration, leaving patients unprotected during an emergency and limiting maximum market penetration.

Other drivers and restraints analyzed in the detailed report include:

1. Growth in Point-of-Care Self-Administration Culture
2. Institutional Stocking Mandates Across Public Spaces
3. Vulnerabilities in Manufacturing and Supply Networks

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

The 0.30 mg format dominated revenue with 47.92% share in 2025 because it targets adults and adolescents who account for most prescriptions. Yet the 0.10 mg pediatric dose advances at a 13.62% CAGR through 2031. The epinephrine autoinjector market size for this strength benefits directly from FDA approval of neffy 1 mg for children weighing 15-30 kg, which arrived in 2025. Pharmacokinetic studies show pediatric users achieve higher epinephrine plasma exposure from nasal delivery than adults, supporting weight-based titration. Manufacturers have redesigned plunger force and needle length for smaller musculature, improving tolerability. Clinics that treat severe infant allergies now maintain three strengths in inventory, widening reorder baskets.

As prescribers match dose to precise weight bands, the 0.15 mg bridge option retains relevance for children graduating from the lowest category. At the upper end, 0.50 mg caters to patients with mast-cell disorders or obesity. Production complexity rises as barrel diameter and spring force vary by SKU, raising tooling costs. Quality control protocols must keep dose-delivery variance tight, especially for pediatric units where under-dosing carries heightened risk. Successful vendors amortise engineering overhead by leveraging modular platform designs and common component families.

Complete Report Scope:

• By Dosage Strength
  • 0.10 mg
  • 0.15 mg
  • 0.30 mg
  • 0.50 mg
• By Age-Group
  • <6 Years
  • 6-12 Years
  • > 12 Years
• By End-User
  • Hospitals
  • Clinics
  • Homecare Individuals
  • Schools & Universities
  • Emergency Medical Services (EMS)
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America remains the largest contributor, delivering 42.25% of 2025 global revenue. The United States blends strong insurance coverage with proactive advocacy by groups such as Food Allergy Research & Education, driving high per-capita device counts. Federal aviation regulations and state price-cap measures add structural floors under demand. Canada's universal pharmacare covers epinephrine for children in multiple provinces, smoothing volume across demographic tiers. Mexico's market is smaller but growing as private insurers extend allergy benefits and urban clinics purchase stock for on-site emergencies.

Asia-Pacific is the fastest growing at an 11.32% CAGR through 2031. Diagnostic capacity is expanding rapidly in tertiary hospitals across China, Japan and South Korea. ARS Pharmaceuticals, through ALK-Abello, filed for neffy approval in all three countries in 2024, signalling confidence in regulatory receptivity. Japan's Ministry of Health already subsidises autoinjectors for paediatric food allergy, although utilisation studies reveal missed opportunities when children forget to carry devices. Awareness campaigns now target parents and sports coaches, reinforcing carriage behaviour. Australia, with long travel distances between medical facilities, regards self-administration devices as critical; its Pharmaceutical Benefits Scheme lists multiple strengths with generous subsidies.

Europe holds a mature but steady share. EMA approval of EURneffy in 2024 set a precedent for alternative delivery systems. Sustainability imperatives resonate: ALK-Abello has pledged a 42% carbon-emission cut by 2030, and procurement consortia in Scandinavia now evaluate life-cycle impact scores alongside price alk.net. Germany's statutory insurance reimburses autoinjectors at fixed reference prices, making generics competitive. The United Kingdom relies on both National Health Service procurement and private-school purchasing, creating dual channels. Italy and Spain have strengthened paediatric-food-allergy guidelines, prompting higher community use.

Emerging territories in the Middle East, Africa and South America still face affordability constraints yet benefit from foreign direct investment in private hospitals and from growing middle-class insurance uptake. Gulf Cooperation Council nations require autoinjectors in large public venues, and medical tourism hubs in the United Arab Emirates stock multiple strengths to cater to visiting patients. Brazil's Anvisa updated anaphylaxis guidelines in 2024, foreshadowing tender opportunities for suppliers who can meet regional labelling and language requirements.

1. Adamis Pharmaceuticals
2. ALK-Abello
3. Amneal Pharmaceuticals
4. Antares Pharma
5. Bausch Health
6. Kalo Inc.
7. Viatris
8. Pfizer
9. Sandoz Group
10. Sanofi
11. Teva Pharmaceutical Industries
12. Emergent Bio Solutions
13. Amedra Pharmaceuticals
14. Lincoln Medical Ltd.
15. SHL Medical
16. Owen Mumford
17. Ypsomed
18. Aptar Pharma
19. West Pharmaceutical Services
20. Becton Dickinson & Co.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Escalating Global Burden of Severe Allergic Disorders
  • 4.2.2 Favorable Regulatory and Reimbursement Ecosystem
  • 4.2.3 Expansion of Generic and Authorized Generic Offerings
  • 4.2.4 Growth In Point-of-Care Self-Administration Culture
  • 4.2.5 Integration of Advanced Digital Health Features
  • 4.2.6 Institutional Stocking Mandates Across Public Spaces
• 4.3 Market Restraints
  • 4.3.1 Persistently High Out-of-Pocket Costs
  • 4.3.2 Vulnerabilities In Manufacturing and Supply Networks
  • 4.3.3 Emergence of Non-Injection Epinephrine Delivery Modalities
  • 4.3.4 Sustainability Concerns Around Disposable Devices
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitute Products
  • 4.5.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Dosage Strength
  • 5.1.1 0.10 mg
  • 5.1.2 0.15 mg
  • 5.1.3 0.30 mg
  • 5.1.4 0.50 mg
• 5.2 By Age-Group
  • 5.2.1 <6 Years
  • 5.2.2 6-12 Years
  • 5.2.3 > 12 Years
• 5.3 By End-User
  • 5.3.1 Hospitals
  • 5.3.2 Clinics
  • 5.3.3 Homecare Individuals
  • 5.3.4 Schools & Universities
  • 5.3.5 Emergency Medical Services (EMS)
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
  • 6.3.1 Adamis Pharmaceuticals Corporation
  • 6.3.2 ALK-Abell A/S
  • 6.3.3 Amneal Pharmaceuticals LLC
  • 6.3.4 Antares Pharma
  • 6.3.5 Bausch & Lomb Inc.
  • 6.3.6 Kalo Inc.
  • 6.3.7 Viatris Inc.
  • 6.3.8 Pfizer Inc.
  • 6.3.9 Sandoz
  • 6.3.10 Sanofi SA
  • 6.3.11 Teva Pharmaceutical Industries Ltd.
  • 6.3.12 Emergent BioSolutions
  • 6.3.13 Amedra Pharmaceuticals
  • 6.3.14 Lincoln Medical Ltd.
  • 6.3.15 SHL Medical
  • 6.3.16 Owen Mumford
  • 6.3.17 Ypsomed
  • 6.3.18 Aptar Pharma
  • 6.3.19 West Pharmaceutical Services
  • 6.3.20 Becton Dickinson & Co.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment